Further Promising Data from Three Studies presented at AACR Meeting
Viralytics Limited (ASX: VLA, OTC: VRACY) is pleased to report a favourable reception to its three poster presentations at theAmerican Association for Cancer Research (AACR) Annual Meeting 2016.

Further details can be found in the announcements on our website:

'MITCI' - CAVATAK / YERVOY Combination in late stage Melanoma
'CALM' Extension - Biopsy analysis of Tumour Microenvironment
Pre-clinical CAVATAK / Checkpoint Inhibitor in Melanoma and Lung

US Investment Bank Roth Capital Partnershas released a fresh report on the company following the latest results. The report can also be found on ourwebsite.

Enquiries

Dr Malcolm McColl
02 9988 4000
Website:www.viralytics.com
About Viralytics Ltd:
Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics' lead investigational product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells. Together this mechanism of action is known as oncolytic immunotherapy. CAVATAK's preferential targeting of cancer cells creates the potential for a more tolerable cancer treatment.

The company has a number of clinical trials in progress, including:
  • An extension to the Phase 2 clinical trial of intratumourally administered CAVATAK in the treatment of Late-Stage Melanoma (the CALM study) in the US which is focused on a deeper understanding of the immunotherapeutic activity of CAVATAK.
  • A Phase 1 clinical trial of intravenously delivered CAVATAK in combination with pembrolizumab (Keytruda®) (via collaboration with Merck) in patients with advanced Non-Small Cell Lung or metastatic Bladder Cancer. Referred to as the STORM (or KEYNOTE-200) study. In the US & UK.
  • A Phase 1 clinical trial of CAVATAK in bladder cancer, known as the CANON study, in the UK.
  • A Phase 1b clinical trial of CAVATAK in combination with YERVOY® (ipilimumab) in late-stage melanoma patients (MITCI study).
  • A Phase 1b clinical trial of CAVATAK in combination with KEYTRUDA® (pembrolizumab) in late-stage melanoma patients (CAPRA study).
Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visitwww.viralytics.com.
Copyright © *2015* *Viralytics Limited*, All rights reserved.

Our mailing address is:
Viralytics Limited
Suite 305, Level 3
66 Hunter Street
Sydney NSW 2000
T: +61 2 9988 4000
F: +61 2 8068 6038
E:Viralytics@viralytics.com

unsubscribe from this listupdate subscription preferences
Tweet
Forward

Viralytics Limited issued this content on 21 April 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 21 April 2016 07:57:05 UTC